LONA (LeonaBio) ROE % Adjusted to Book Value: -174.44% (As of Mar. 2026)

LeonaBio LONA -0.79% 28 ROE % Adjusted to Book Value is -174.44% as of Mar. 2026. GuruFocus rates LONA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

LeonaBio's ROE % for the quarter that ended in Mar. 2026 was -341.90%. LeonaBio's PB Ratio for the quarter that ended in Mar. 2026 was 1.96. LeonaBio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -174.44%.

LeonaBio ROE % Adjusted to Book Value Related Terms

LeonaBio ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for LeonaBio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LeonaBio ROE % Adjusted to Book Value Chart

LeonaBio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-12.13

-67.43

-90.73

-217.20

-114.49

LeonaBio Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-296.70	-217.30	-147.52	-478.35	-174.44

LONA vs ICCC, TELO, PYPD: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, LeonaBio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LeonaBio ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LeonaBio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where LeonaBio's ROE % Adjusted to Book Value falls into.

Save Embed

28GF Score

LeonaBio Inc LONA

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

LeonaBio ROE % Adjusted to Book Value Calculation

LeonaBio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-290.81%	/	2.54
	=	-114.49%

LeonaBio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-341.90%	/	1.96
	=	-174.44%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of -174.44% mean?

LeonaBio (LONA) has a ROE % Adjusted to Book Value of -174.44% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on LeonaBio and its competitors.

Is LeonaBio's ROE % Adjusted to Book Value too high?

LeonaBio's current ROE % Adjusted to Book Value is -174.44%. Overall, LeonaBio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does LeonaBio's ROE % Adjusted to Book Value compare to ICCC and TELO?

LeonaBio's ROE % Adjusted to Book Value of -174.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on LeonaBio and its competitors. LeonaBio's current ROE % Adjusted to Book Value is -174.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is LeonaBio stock overvalued right now?

LeonaBio (LONA) has a current ROE % Adjusted to Book Value of -174.44%. The current ROE % Adjusted to Book Value is -174.44%. LeonaBio's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For LeonaBio (LONA), the current ROE % Adjusted to Book Value is -174.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LeonaBio Business Description

Industry Healthcare Biotechnology

Comparable Companies ICCC TELO PYPD MAIA NRXS CRDF INO FBIO RLYB SEER VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011

Website https://www.leonabio.com

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

28GF Score

Get the complete analysis for LONA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.80

Price

View LONA Analysis

See ROE % Adjusted to Book Value data for all stocks →